Want to see SDGR full AI Analyst Report?
SDGR Stock Chart & Stats
$14.97
-$0.16(-1.06%)
At close: 4:00 PM EDT
$14.97
-$0.16(-1.06%)
Day’s Range― - ―
52-Week Range$10.95 - $23.02
Previous CloseN/A
Volume981.72K
Average Volume (3M)1.23M
Market Cap
$1.48B
Enterprise Value$920.43
Total Cash (Recent Filing)$413.74M
Total Debt (Recent Filing)$107.98M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Nov 11, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding65,641,430
10 Day Avg. Volume895,288
30 Day Avg. Volume1,233,227
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.61
Price to Sales (P/S)5.13
P/FCF Ratio105.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside33.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$240.32M
Bulls Say, Bears Say
Bulls Say
Recurring Contract GrowthStrong ACV growth indicates sustained customer adoption of Schrödinger’s software platform. Expansion in recurring contract value can improve revenue visibility and reinforce the company’s position in computational chemistry.
Platform ExpansionBunsen and major technology and biopharma relationships broaden Schrödinger’s platform reach. If deployments convert into throughput-based licensing, they can expand the addressable market and deepen customer integration.
Liquidity And Cost DisciplineSubstantial liquidity gives Schrödinger capacity to fund product development and drug programs while absorbing commercialization volatility. Lower operating expenses also support a path toward improved operating leverage as revenue scales.
Bears Say
Persistent Losses And Cash BurnDespite strong revenue growth, Schrödinger remains dependent on its cash reserves to fund operations. Continued losses and negative free cash flow could constrain investment flexibility and make sustainable profitability dependent on successful scale.
Hosted Transition PressureThe move to hosted licensing should support a more modern delivery model, but its ratable revenue recognition creates a multi-quarter financial headwind. Lower near-term margins and reported revenue could complicate execution and profitability improvement.
Slow New-Product AdoptionLong evaluation cycles delay broad commercialization of new products and make near-term growth reliant on the established platform. Schrödinger must convert pilots into recurring contracts while continuing to fund development and customer support.
Schrodinger News
SDGR FAQ
What was Schrodinger, Inc.’s price range in the past 12 months?
Schrodinger, Inc. lowest stock price was $10.95 and its highest was $23.02 in the past 12 months.
What is Schrodinger, Inc.’s market cap?
Schrodinger, Inc.’s market cap is $1.48B.
When is Schrodinger, Inc.’s upcoming earnings report date?
Schrodinger, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were Schrodinger, Inc.’s earnings last quarter?
Schrodinger, Inc. released its earnings results on Aug 05, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.494.
Is Schrodinger, Inc. overvalued?
According to Wall Street analysts Schrodinger, Inc.’s price is currently Undervalued.
Does Schrodinger, Inc. pay dividends?
Schrodinger, Inc. does not currently pay dividends.
What is Schrodinger, Inc.’s EPS estimate?
Schrodinger, Inc.’s EPS estimate is -0.7.
How many shares outstanding does Schrodinger, Inc. have?
Schrodinger, Inc. has 65,641,430 shares outstanding.
What happened to Schrodinger, Inc.’s price movement after its last earnings report?
Schrodinger, Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 8.598%.
Which hedge fund is a major shareholder of Schrodinger, Inc.?
Currently, no hedge funds are holding shares in SDGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Schrodinger Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (33.60% Upside)
$20.00 (33.60% Upside)
Blogger Sentiment
Neutral
SDGR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 202.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.95%
Trailing 12-Months
Company Description
Schrodinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Company Deck
SDGR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum driven by robust ACV growth, accelerating hosted adoption, the early launch and customer deployment of Bunsen, notable one-time collaboration milestones (e.g., $10M Ajax milestone) and a return to quarterly profitability with a solid cash position. Counterbalancing this optimism are near-term margin and revenue recognition pressures from the accelerated hosted licensing transition, a decline in contribution revenue tied to grant timing, and multi-quarter adoption timelines for new products like predictive toxicology. Guidance shows moderate full-year ACV growth (10%–15%), reflecting a more conservative outlook than Q2’s run-rate. Overall, positives around product innovation, customer expansion, and financial position outweigh the transitional challenges while leaving some execution and timing risks to monitor.View all SDGR earnings summariesSDGR Stock 12 Month Forecast
Average Price Target
$20.00
▲(33.60% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
17.42% Mutual Funds
37.03% Other Institutional Investors
15.73% Public Companies and
Individual Investors